MedTrace Logo

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

NCT00545519 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2013-04-23

No results posted yet for this study

Summary

To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients.

To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with Thymoglobulin.

To determine the time to response, duration of response, and time to progression and overall survival of patients treated with Thymoglobulin.

To determine the safety and tolerability of Thymoglobulin in these patients.

To assess the changes in lymphocyte apoptosis and apoptotic signaling in treated patients.

Conditions

Interventions

DRUG

thymoglobulin

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Ravi Vij, M.D. · Washington Universtiy in St. Louis

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00545519 on ClinicalTrials.gov